Washington – The US Food and Drug Administration (FDA) has authorised a monoclonal antibody drug against Covid-19, developed by GlaxoSmithKline and Vir. They claim it reduces hospitalisation and death among Coronavirus patients by 85 per cent and is also effective against the variants. Laboratory tests have shown that Sotrovimab is able to neutralise the current circulating variants of Covid first reported in the UK, South Africa, Brazil, California, New York and India. Patrizia Cavazzoni, Director of the FDA’s Center for Drug Evaluation and Research, said in a statement: “With the authorisation of this monoclonal antibody treatment, we are providing another option to help keep high-risk patients with Covid-19 out of the hospital. It is important to expand the arsenal of monoclonal antibody therapies that are expected to retain activity against the circulating variants of Covid-19 in the United States.” The drug, the FDA said, will be distributed and administered as a 500 milligram single dose intravenously by health care providers. Potential side effects of Sotrovimab include anaphylaxis and infusion-related reactions, rash and diarrhoea.